Targeted Delivery of Validated Therapeutic Agents
Making Great Therapies Greater
Transforming validated therapeutics by enabling targeted delivery and improving pharmacokinetics
Platform Technology
The MB technology platform is widely adaptable for use with proteins, peptides or other small molecules.
Read more…
Innovative Approach
ProteoThera’s novel approach to solving complex pharmacokinetic problems opens new development opportunities for previously validated therapeutics.
Read more…
Research Collaborations
ProteoThera is actively identifying research collaborations. If you are interested in learning how MB technology can transform your therapy, please contact us…
Read more…The platform
Keep the drug where it is needed
ProteoThera’s platform fuses a validated therapeutic to a short matrix-binding peptide. The fusion binds proteoglycans in the tissue matrix, so the drug stays in the joint instead of leaving into systemic circulation.
The first programme
PRT-1000, for acute gout pain
A matrix-binding form of interleukin-1 receptor antagonist — a drug already approved systemically for rheumatoid arthritis — delivered locally where the flare is.
Latest news
On the record
-
9 May 2016
ProteoThera, Inc. Receives Allowance for a Broad U.S. Patent Covering Matrix-Binding Technology Platform
NEWTON, Massachusetts – May 9, 2016 – ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced that it has received a notice of allowance for a broad U.S. patent covering its matrix-binding technology platform.
-
8 January 2016
Targeted Drug-Delivery Company ProteoThera, Inc. To Present At BioTech Showcase™ Monday, Jan. 11 at 11:30 am PT
NEWTON, Massachusetts – January 8, 2016 – ProteoThera, Inc. announced that its Chief Executive Officer, Patrick O’Donnell, would present the Company’s targeted drug-delivery platform technology, internal product development strategy and research collaboration opportunities at the 8th annual BioTech Showcase conference. Dr. Parth Patwari, ProteoThera’s Chief Science Officer, was also in attendance.
-
2 December 2015
United States PTO Grants a Key Patent Supporting The ProteoThera Matrix-Binding Technology Platform
NEWTON, Massachusetts – December 2, 2015 – ProteoThera announced a notice of grant from the USPTO for a fundamental patent entitled “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences”, U.S. patent number 9,187,517, to which ProteoThera holds exclusive worldwide rights through its existing agreement with Brigham and Women’s Hospital.